XLON
DOCS
Market cap859mUSD
Oct 09, Last price
68.00GBP
1D
2.57%
1Q
-6.22%
IPO
-84.88%
Name
Dr Martens PLC
Chart & performance
P/E
27.35
P/S
0.85
EPS
0.02
Div yield, %
3.76%
Shrs. gr., 5y
-0.42%
Rev. gr., 5y
-0.21%
Revenues
765m
-2.88%
Net income
24m
+428.89%
CFO
126m
-36.07%
Dividend
Aug 27, 20261.7 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dr. Martens Plc engages in the manufacture and sale of footwear products. The firm offers boots, shoes, sandals, shoe care products, laces, and socks. It operates through the following geographical segments: EMEA, Americas, and APAC. The company was founded by Klaus Maertens in 1945 and is headquartered in London, the United Kingdom.
Key people
Paul Mason
Non-Executive Chairman of the Board · since 2021
Kenny Wilson
Chief Executive Officer, Executive Director · since 2018
Derek Chan
President, APAC · since 2019
Mike Stopforth
President, EMEA · since 2023
Chief Operating Officer · since 2018
Bridget Jolliffe
Chief People Officer · since 2024
Graham Calder
Chief Technology Officer · since 2023
Giles Wilson
Chief Financial Officer, Executive Director · since 2024
Adam Meek
Chief Product Officer · since 2021
Ije Nwokorie
Chief Brand Officer · since 2024
Erik Zambon
Strategy Director · since 2017
Katherine Bellau
Company Secretary · since 2024
Emily Reichwald
Chief Sustainability Officer and Company Secretary · since 2024
Tara Alhadeff
Non-Independent Non-Executive Director · since 2015
Benoit Vauchy
Non-Independent Non-Executive Director · since 2025
Non-Executive Independent Director · since 2025
Independent Non-Executive Director · since 2023
Independent Non-Executive Director · since 2021
Ian Rogers
Independent Non-Executive Director · since 2021
Senior Non-Executive Independent Director · since 2021
Headquarters & legal address
28 JAMESTOWN ROAD
CAMDEN
LONDON, LND NW1 7BY
GB
CAMDEN
LONDON, LND NW1 7BY
GB
Previous name
DR. MARTENS LIMITED
Previous name
DR MARTENS LIMITED
Previous name
AMPHOLDCO LIMITED
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||